Cyclodextrin scientists in the finals for European Inventor Award 2023
Inventors, who made a significant contribution to innovation, economy and society in Europe have been awarded since 2006 by the
Author: zoltanfulop
Oculis goes public on the Nasdaq Stock Market
Oculis the Icelandic (now global) ophthalmology company, founded by Thorsteinn Loftsson and Einar Stefánsson, celebrated its public listing on the
Recent important review articles from Thorsteinn Loftsson’s group about ophthalmic drug delivery
Thorsteinn Loftsson recently published a series of review articles which sums up his advances in ophthalmic drug delivery. This blog
Are cyclodextrins safe for intravitreal injections?
Cyclodextrins are excellent excipients for various routes of administration, the ophthalmic delivery is potentially one of the most useful applications
BIO Digital 2021
The yearly exhibition, conference and partnering event of the Biotechnology Innovation Organization (BIO), will be held between June 10-11 and
Oculis Successful End-Of-Phase 2 Meeting With The FDA, On Towards Phase 3
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently announced that they are progressing towards Phase 3 with OCS-01 in two
Oculis Top-Line data from Phase 2 clinical trial for OCS-01 treating inflammation and pain after cataract surgery
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently reported new clinical data at the Americal Society of Cataract and Refractive
Cyclo Therapeutics reports international patent application for treating Alzheimer’s
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
Nasal delivery with beta-cyclodextrin is approved; a short story of Baqsimi
Cyclodextrins have not been popular excipients for nasal or pulmonary drug delivery so far. This can change soon, with the
Oculis aces the Phase 2 clinical trial for OCS-01 treating DME
Oculis reported positive results from Phase 2 clinical studies of OCS-01 for treating DME